GSK seeks FDA approval of Fluarix

GlaxoSmithKline has moved for FDA approval of its flu vaccine Fluarix. If approved, it would become the fourth flu vaccine approved for the US market and could help stabilize the market for the drug. Last season's decision to shutter Chiron's UK plant for flu vaccine eliminated half the needed supply of flu vaccine in the US. GSK sells Fluarix in 75 countries and provided some of the drug to US distributors last winter on an emergency basis.

"Right now a limited number of companies supply injectable flu vaccine to the entire nation, making the system vulnerable when there are problems with supply as we saw last flu season," said Christopher Viehbacher, GlaxoSmithKline's president of US Pharmaceuticals, in a statement.

- read this story from TheStreet.com for more on Fluarix

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.